SANOFI-AVENTIS (EPA:SAN) | Finanzwire

Basculer en Français

8302	Companies
115121	Keywords
55446	Articles
62530	Press releases

Home
Companies
SANOFI-AVENTIS

BRIEF

published on 06/21/2024 at 07:05, 5 months ago

Sanofi strengthens its leadership in the treatment of hemophilia

Sanofi Fitusiran ISTH Haemophilia ALTUVIIO
PRESS RELEASE

published on 06/21/2024 at 07:00, 5 months ago

Press Release: ISTH: Sanofi advances leadership in hemophilia with new data for ALTUVIIIO and fitusiran
Sanofi presents new data on ALTUVIIIO and fitusiran at ISTH Congress, showcasing potential first- and best-in-class treatments for hemophilia. Fitusiran NDA under FDA review with PDUFA date of March 28, 2025

Sanofi ALTUVIIIO Fitusiran Hemophilia ISTH Congress
BRIEF

published on 06/12/2024 at 20:24, 5 months 9 days ago

Sanofi: Information on voting rights and shares - May 2024

Voting Rights Investors Actions Sanofi May 2024
PRESS RELEASE

published on 06/12/2024 at 20:19, 5 months 9 days ago

Sanofi: Information concerning the total number of voting rights and shares – May 2024
Sanofi discloses total number of voting rights and shares as per French commercial code and stock market authority regulations. Details available on Sanofi's website

Voting Rights French Commercial Code Shares Sanofi Stock Market Authority
BRIEF

published on 06/03/2024 at 22:20, 5 months 18 days ago

Phase III study: Sarclisa improves progression-free survival of patients with multiple myeloma

Multiple Myeloma Sarclisa ASCO Phase III Study Progression-free Survival
PRESS RELEASE

published on 06/03/2024 at 22:15, 5 months 18 days ago

Press Release: ASCO: Sarclisa is first anti-CD38 to significantly improve progression-free survival in combination with VRd for newly diagnosed transplant-ineligible multiple myeloma in phase 3
Sarclisa in combo with VRd significantly enhances progression-free survival in newly diagnosed transplant-ineligible multiple myeloma in phase 3 study at ASCO. Full data published in NEJM

Multiple Myeloma Phase 3 Sarclisa Progression-free Survival VRd
BRIEF

published on 05/31/2024 at 12:05, 5 months 21 days ago

Sanofi Launches 2024 Global Employee Stock Purchase Plan

Financial Investment Sanofi Employee Stock Purchase Plan Action 2024 Global Participation
PRESS RELEASE

published on 05/31/2024 at 12:00, 5 months 21 days ago

Press Release: Sanofi launches 2024 global Employee Stock Purchase Plan
Sanofi launches 2024 global Employee Stock Purchase Plan, Action 2024, offering discounted shares to 80,000 employees in 56 countries. CEO Paul Hudson affirms commitment to employee participation and company growth

Company Growth Sanofi Employee Stock Purchase Plan Action 2024 Employee Shareholders
BRIEF

published on 05/31/2024 at 07:10, 5 months 21 days ago

CHMP recommends approval of Dupixent in the EU for the treatment of patients with COPD

Sanofi COPD Dupixent CHMP Supply
PRESS RELEASE

published on 05/31/2024 at 07:05, 5 months 21 days ago

Press Release: Dupixent recommended for EU approval by the CHMP to treat patients with COPD
European Medicines Agency's CHMP recommends Dupixent for EU approval to treat uncontrolled COPD with raised blood eosinophils. If approved, it would be the first targeted therapy for COPD in the EU

Dupixent CHMP EU Approval COPD Treatment Type 2 Inflammation

Accesswire

Published on 11/21/2024 at 22:05, 1 hour 21 minutes ago

Protagonist Announces Nomination of PN-881, a Potential Best-in-Class Oral Peptide IL-17 Antagonist Development Candidate
Published on 11/21/2024 at 21:50, 1 hour 36 minutes ago

Seventy Ninth Resources Announces Successful First Reconnaissance at McKellar Copper-Zinc and Enable Gold Projects
Published on 11/21/2024 at 20:15, 3 hours 11 minutes ago

Woodland Park Zoo Awarded Transformative Grant to Advance Empathy for Animals
Published on 11/21/2024 at 20:10, 3 hours 16 minutes ago

For Us TV Productions, a Portfolio Company of Belle Bonica Luxe Corp., Invites BIPOC Filmmakers and Producers to Join Its Inclusive Streaming Platform
Published on 11/21/2024 at 20:00, 3 hours 26 minutes ago

Victory for New York Homeowners: Petroff Amshen LLP Blocks Lender’s Repeated Foreclosure Attempt

View all ACCESSWIRE

EQS Group

Published on 11/21/2024 at 19:01, 4 hours 24 minutes ago

Fuller, Smith & Turner PLC: Transaction in own shares
Published on 11/21/2024 at 18:36, 4 hours 50 minutes ago

Original-Research: Beaconsmind AG (von First Berlin Equity Research GmbH): BUY
Published on 11/21/2024 at 17:58, 5 hours 27 minutes ago

Funding Circle Plc: POS-Transaction in Own Shares
Published on 11/21/2024 at 17:51, 5 hours 34 minutes ago

LIGHTON announces highly successful IPO on Euronext Growth Paris.
Published on 11/21/2024 at 17:51, 5 hours 34 minutes ago

2CRSi SA: 2CRSi supplies Exaion, a subsidiary of the EDF Group, with high-performance immersion servers in North America.

Les Echos

Published on 11/21/2024 at 06:58, 16 hours 28 minutes ago

Net Asset Value per share increases with 9.4% in six months to EUR 55.6 thanks to continued strong growth performance of the portfolio
Published on 11/20/2024 at 19:20, 1 day 4 hours ago

Peugeot Invest Board of Directors to evolve following the May 2025 Annual General Meeting
Published on 11/20/2024 at 17:45, 1 day 5 hours ago

MEDESIS PHARMA HAS COMPLETED ITS CLINICAL STUDY FOR THE TREATMENT OF ALZHEIMER'S DISEASE WITH NANOLITHIUM
Published on 11/20/2024 at 17:45, 1 day 5 hours ago

Disclosure of Share Capital and Voting Rights Outstanding as of October 31, 2024
Published on 11/20/2024 at 07:45, 1 day 15 hours ago

Gimv sells to Fremman Capital a majority stake in outpatient rehabilitation specialist rehaneo

View all LES ECHOS COMFI WIRE